The Inflation Reduction Act of 2022 has triggered a raft of changes to Medicare Part D plans and Medicare Advantage plans that affect prescription drug coverage in 2025. Here’s what to know.
A short statement from CMS said the agency will consider ways to make Medicare price negotiations, begun under Biden, more ...
The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...
The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...
Trump stopped a program that had been in the works and was intended to give Medicare recipients access to more than 100 ...
Biden-era policies rescinded by Donald Trump could signal a significant shake-up in Medicare and Medicaid drug price reforms.
Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of nearly $120 billion, finds itself at a critical juncture as it navigates a complex landscape of ...
The White House rescinded a pause on all Federal grants and loans, but the short-lived action shined a light on what could ...
A day later, Morrisons confirmed it was getting rid of 201 roles as part of a major cost-cutting ... and combined with a slight reduction in average borrowing costs, it had become more affordable ...
On the one hand, falling inflation and interest rates should provide ... the Labour government has confirmed rent controls will not be part of its Renters' Rights Bill, nor will it grant London ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback